Let me first say I have no medical qualifications.
With no side affects to speak of it would seem to be the ideal companion drug for many ailments and in many instances it could be the first treatment due to its ease of delivery being a tablet.
The second page on this ASX Release states just that. https://www.pharmaust.com/clinical-trial-report-following-phase-i-trial/
of course that was back in 2015. Since then PAA have had a few hills to climb but now with the reformulation complete, it seems the only!! hill now is funding.
We have two irons in the fire with regards the funding bit, the lymphoma in dogs tests being done by the Heart of Texas who are member of Thrive Pet Health Care could be a good out come for PAA thanks to Dr Kim Agnew. And the upcoming MND trial. IMO (but you knew all that)
Good luck to all
- Forums
- ASX - By Stock
- PAA
- MND Phase 1/2/3 Trial review what to expect. The Chemistry !
MND Phase 1/2/3 Trial review what to expect. The Chemistry !, page-15
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
17.3¢ |
Change
-0.008(4.17%) |
Mkt cap ! $83.90M |
Open | High | Low | Value | Volume |
18.0¢ | 18.0¢ | 17.3¢ | $59.77K | 338.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 376984 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 25091 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 366984 | 0.170 |
7 | 256513 | 0.165 |
9 | 399304 | 0.160 |
6 | 336734 | 0.155 |
8 | 227993 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 252275 | 4 |
0.185 | 367471 | 6 |
0.190 | 820111 | 8 |
0.195 | 593409 | 10 |
0.200 | 302726 | 11 |
Last trade - 15.42pm 13/09/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online